Technical Analysis for CBAY - CymaBay Therapeutics Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Very Strong | Up | Up | Flat |
Date | Alert Name | Type | % Chg |
---|---|---|---|
New 52 Week Closing High | Bullish | 26.35% | |
New Uptrend | Bullish | 26.35% | |
New 52 Week High | Strength | 26.35% | |
MACD Bullish Signal Line Cross | Bullish | 30.05% | |
New 52 Week Closing High | Bullish | 30.05% | |
Pocket Pivot | Bullish Swing Setup | 30.05% | |
Bollinger Band Squeeze | Range Contraction | 30.05% | |
New 52 Week High | Strength | 30.05% | |
BB Squeeze + Upper Band Touch | Range Contraction | 30.05% | |
Above Upper BB | Strength | 30.05% |
Alert | Time |
---|---|
No Alerts Yet. Alerts will only show here if at least one person is tracking alerts on this stock. |
Free Daily (Stock) Chart Reading
- Earnings date: 03/14/2024
CymaBay Therapeutics Inc. Description
Cymabay Therapeutics, Inc. focuses on developing therapies to treat metabolic diseases. Its lead product candidate is Arhalofenate, which completed five Phase II clinical trials for the treatment of gout. The company's product candidate also includes MBX-8025, a selective agonist that is in a Phase II clinical trial in patients with mixed dyslipidemia; and MBX-2982, an oral, G-protein coupled receptor agonist to treat type II diabetes. Cymabay Therapeutics, Inc. has a development and license agreements with Janssen Pharmaceuticals, Inc. to develop and discover undisclosed metabolic disease target agonists for the treatment of T2DM and other disorders; and a license and development agreement with DiaTex, Inc. to develop and commercialize therapeutic products. The company was formerly known as Metabolex, Inc. Cymabay Therapeutics, Inc. was incorporated in 1988 and is based in Newark, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Diabetes Health Care Disorders Therapeutic Products Lipid Metabolic Disease Regulus Therapeutics Dyslipidemia Type I Diabetes Type II Diabetes Gout Mixed Dyslipidemia
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 32.48 |
52 Week Low | 7.2609 |
Average Volume | 4,263,780 |
200-Day Moving Average | 18.07 |
50-Day Moving Average | 28.06 |
20-Day Moving Average | 32.31 |
10-Day Moving Average | 32.38 |
Average True Range | 0.31 |
RSI (14) | 81.10 |
ADX | 67.74 |
+DI | 42.03 |
-DI | 5.94 |
Chandelier Exit (Long, 3 ATRs) | 31.54 |
Chandelier Exit (Short, 3 ATRs) | 33.06 |
Upper Bollinger Bands | 32.51 |
Lower Bollinger Band | 32.10 |
Percent B (%b) | 0.87 |
BandWidth | 1.29 |
MACD Line | 1.19 |
MACD Signal Line | 1.49 |
MACD Histogram | -0.3035 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 32.51 | ||||
Resistance 3 (R3) | 32.51 | 32.49 | 32.50 | ||
Resistance 2 (R2) | 32.49 | 32.48 | 32.49 | 32.49 | |
Resistance 1 (R1) | 32.48 | 32.47 | 32.48 | 32.48 | 32.49 |
Pivot Point | 32.46 | 32.46 | 32.46 | 32.46 | 32.46 |
Support 1 (S1) | 32.45 | 32.45 | 32.45 | 32.45 | 32.43 |
Support 2 (S2) | 32.43 | 32.44 | 32.43 | 32.43 | |
Support 3 (S3) | 32.42 | 32.43 | 32.42 | ||
Support 4 (S4) | 32.42 |